Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 2Radiation Injuries 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Melanoma 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, T-Cell 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia 1Hodgkin Disease 1HTLV-I Infections 1Diabetes Mellitus, Insulin-Dependent, 10 1

Interventions

Cyclophosphamide 2ruxolitinib 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1brincidofovir 1Vincristine 1Raltegravir Potassium 1Prednisone 1Etoposide 1Doxorubicin 1Daclizumab 1Bortezomib 1B3(Fv)-PE38KDEL recombinant immunotoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia-Lymphoma, Adult T-Cell × Daclizumab × Clear all
NCT00001941 2012-08-20

Anti-Tac for Treatment of Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 12 charts
LymphoidOther hematologic neoplasm

Diabetes Mellitus, Insulin-Dependent, 10, Leukemia, T-Cell, Leukemia-Lymphoma, Adult T-Cell, HTLV-I Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡